126 related articles for article (PubMed ID: 17828695)
1. Risk factors for and impact of infection or colonization with aztreonam-resistant Pseudomonas aeruginosa.
Gasink LB; Fishman NO; Nachamkin I; Bilker WB; Lautenbach E
Infect Control Hosp Epidemiol; 2007 Oct; 28(10):1175-80. PubMed ID: 17828695
[TBL] [Abstract][Full Text] [Related]
2. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes.
Lautenbach E; Synnestvedt M; Weiner MG; Bilker WB; Vo L; Schein J; Kim M
Infect Control Hosp Epidemiol; 2010 Jan; 31(1):47-53. PubMed ID: 19951202
[TBL] [Abstract][Full Text] [Related]
3. Imipenem resistance among pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes.
Lautenbach E; Weiner MG; Nachamkin I; Bilker WB; Sheridan A; Fishman NO
Infect Control Hosp Epidemiol; 2006 Sep; 27(9):893-900. PubMed ID: 16941312
[TBL] [Abstract][Full Text] [Related]
4. Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact.
Gasink LB; Fishman NO; Weiner MG; Nachamkin I; Bilker WB; Lautenbach E
Am J Med; 2006 Jun; 119(6):526.e19-25. PubMed ID: 16750968
[TBL] [Abstract][Full Text] [Related]
5. Risk of developing pneumonia is enhanced by the combined traits of fluoroquinolone resistance and type III secretion virulence in respiratory isolates of Pseudomonas aeruginosa.
Sullivan E; Bensman J; Lou M; Agnello M; Shriner K; Wong-Beringer A
Crit Care Med; 2014 Jan; 42(1):48-56. PubMed ID: 23963124
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome.
Joo EJ; Kang CI; Ha YE; Kang SJ; Park SY; Chung DR; Peck KR; Lee NY; Song JH
Microb Drug Resist; 2011 Jun; 17(2):305-12. PubMed ID: 21381966
[TBL] [Abstract][Full Text] [Related]
7. Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes.
Hsu DI; Okamoto MP; Murthy R; Wong-Beringer A
J Antimicrob Chemother; 2005 Apr; 55(4):535-41. PubMed ID: 15728150
[TBL] [Abstract][Full Text] [Related]
8. Pseudomonas aeruginosa Infection after Pancreatoduodenectomy: Risk Factors and Clinic Impacts.
Zhang JF; Zhu HY; Sun YW; Liu W; Huo YM; Liu DJ; Li J; Hua R
Surg Infect (Larchmt); 2015 Dec; 16(6):769-74. PubMed ID: 26237502
[TBL] [Abstract][Full Text] [Related]
9. Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa.
Eagye KJ; Kuti JL; Nicolau DP
Infect Control Hosp Epidemiol; 2009 Aug; 30(8):746-52. PubMed ID: 19583513
[TBL] [Abstract][Full Text] [Related]
10. Use of aztreonam in association with cefepime for the treatment of nosocomial infections due to multidrug-resistant strains of Pseudomonas aeruginosa to β-lactams in ICU patients: A pilot study.
Dupont H; Marciniak S; Zogheib E; Mammeri H; Friggeri A; Ammenouche N; Levrard M; Airapetian N; Tinturier F; Mahjoub Y
Anaesth Crit Care Pain Med; 2015 Jun; 34(3):141-4. PubMed ID: 26004874
[TBL] [Abstract][Full Text] [Related]
11. Investigation of a nosocomial outbreak by alginate-producing pan-antibiotic-resistant Pseudomonas aeruginosa.
Yakupogullari Y; Otlu B; Dogukan M; Gursoy C; Korkmaz E; Kizirgil A; Ozden M; Durmaz R
Am J Infect Control; 2008 Dec; 36(10):e13-8. PubMed ID: 19084158
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Microb Drug Resist; 2005; 11(1):68-74. PubMed ID: 15770098
[TBL] [Abstract][Full Text] [Related]
13. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance.
Micek ST; Wunderink RG; Kollef MH; Chen C; Rello J; Chastre J; Antonelli M; Welte T; Clair B; Ostermann H; Calbo E; Torres A; Menichetti F; Schramm GE; Menon V
Crit Care; 2015 May; 19(1):219. PubMed ID: 25944081
[TBL] [Abstract][Full Text] [Related]
14. Acquisition of Pseudomonas aeruginosa and its resistance phenotypes in critically ill medical patients: role of colonization pressure and antibiotic exposure.
Cobos-Trigueros N; Solé M; Castro P; Torres JL; Hernández C; Rinaudo M; Fernández S; Soriano Á; Nicolás JM; Mensa J; Vila J; Martínez JA
Crit Care; 2015 May; 19(1):218. PubMed ID: 25936721
[TBL] [Abstract][Full Text] [Related]
15. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
Master RN; Clark RB; Karlowsky JA; Ramirez J; Bordon JM
Int J Antimicrob Agents; 2011 Oct; 38(4):291-5. PubMed ID: 21737249
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for recovery of imipenem- or ceftazidime-resistant pseudomonas aeruginosa among patients admitted to a teaching hospital in Brazil.
Fortaleza CM; Freire MP; Filho Dde C; de Carvalho Ramos M
Infect Control Hosp Epidemiol; 2006 Sep; 27(9):901-6. PubMed ID: 16941313
[TBL] [Abstract][Full Text] [Related]
17. Pseudomonas aeruginosa Colonization in the Intensive Care Unit: Prevalence, Risk Factors, and Clinical Outcomes.
Harris AD; Jackson SS; Robinson G; Pineles L; Leekha S; Thom KA; Wang Y; Doll M; Pettigrew MM; Johnson JK
Infect Control Hosp Epidemiol; 2016 May; 37(5):544-8. PubMed ID: 26832307
[TBL] [Abstract][Full Text] [Related]
18. Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections.
Peña C; Cabot G; Gómez-Zorrilla S; Zamorano L; Ocampo-Sosa A; Murillas J; Almirante B; Pomar V; Aguilar M; Granados A; Calbo E; Rodríguez-Baño J; Rodríguez-López F; Tubau F; Martínez-Martínez L; Oliver A;
Clin Infect Dis; 2015 Feb; 60(4):539-48. PubMed ID: 25378459
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multi-drug resistant Pseudomonas aeruginosa and Acinetobacter spp.
Sader HS; Jones RN
Int J Antimicrob Agents; 2005 May; 25(5):380-4. PubMed ID: 15848291
[TBL] [Abstract][Full Text] [Related]
20. Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa-infected patients.
Judd WR; Ratliff PD; Hickson RP; Stephens DM; Kennedy CA
Am J Infect Control; 2016 Nov; 44(11):1275-1279. PubMed ID: 27320901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
